SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Andersson Henrik A.)
 

Sökning: WFRF:(Andersson Henrik A.) > (2010-2014) > The safety of fleca...

The safety of flecainide treatment of atrial fibrillation : long-term incidence of sudden cardiac death and proarrhythmic events

Almroth, Henrik, 1970- (författare)
Örebro universitet,Institutionen för hälsovetenskap och medicin,Department of Cardiology, Örebro University Hospital, Örebro, Sweden
Andersson, Tommy (författare)
Department of Cardiology, Örebro University Hospital, Örebro, Sweden
Fengsrud, Espen, 1970- (författare)
Örebro universitet,Institutionen för hälsovetenskaper,Department of Cardiology, Örebro University Hospital, Örebro, Sweden
visa fler...
Friberg, Leif (författare)
Karolinska Institutet
Linde, P. (författare)
Department of Cardiology, Örebro University Hospital, Örebro, Sweden
Rosenqvist, Mårten (författare)
Karolinska Institutet
Englund, A. (författare)
Stockholm South Hospital, Karolinska Institutet, Stockholm, Sweden
visa färre...
 (creator_code:org_t)
2011-06-02
2011
Engelska.
Ingår i: Journal of Internal Medicine. - : John Wiley & Sons. - 0954-6820 .- 1365-2796. ; 270:3, s. 281-290
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objective:To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) andproarrhythmic events.Design: Retrospective,observational cohort study.Setting.Single-centre study at Örebro University Hospital, Sweden.Setting: Single-centre study at Orebro University Hospital, Sweden.Subjects: A total of 112 patients with paroxysmal (51%) or persistent (49%) AF (mean age 60 ± 11 years) were included after identifying all patients with AF who initiated oral flecainide treatment (mean dose 203 ± 43 mg per day) between 1998 and 2006. Standard exclusion⁄inclusion criteria for flecainide were used,andflecainidetreatmentwasusually combined withanatrioventricular-blocking agent (89%).Main outcome measure: Death was classified as sudden or nonsudden according to standard definitions. Proarrhythmia was defined as cardiac syncope or lifethreatening arrhythmia.Results: Eight deaths were reported during a mean follow- up of 3.4 ± .4 years. Compared to the general population, the standardized mortality ratios were 1.57 (95% confidence interval (CI) 0.68–3.09) for allcause mortality and 4.16 (95% CI 1.53–9.06) for death from cardiovascular disease. Three deaths were classified as SCDs. Proarrhythmic events occurred in six patients (two each with wide QRS tachycardia, 1 : 1 conducted atrial flutter and syncope during exercise).Conclusion: We found an increased incidence of SCD or proarrhythmic events in this real-world study of flecainide used for the treatment of AF. The findings suggest that further investigation into the safety of flecainide for the treatment of patients with AF is warranted.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Allmänmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- General Practice (hsv//eng)

Nyckelord

atrial fibrillation
flecainide
proarrhythmia
safety
sudden cardiac death

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy